- Home
- FINW vs VIGL Comparison
FINW vs VIGL Comparison
Compare FINW & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- VIGL
- Stock Information
- Founded
- FINW 1999
- VIGL 2020
- Country
- FINW United States
- VIGL United States
- Employees
- FINW N/A
- VIGL N/A
- Industry
- FINW Commercial Banks
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- VIGL Health Care
- Exchange
- FINW Nasdaq
- VIGL Nasdaq
- Market Cap
- FINW 170.0M
- VIGL 148.7M
- IPO Year
- FINW 2021
- VIGL 2022
- Fundamental
- Price
- FINW $14.20
- VIGL $3.68
- Analyst Decision
- FINW Buy
- VIGL Buy
- Analyst Count
- FINW 1
- VIGL 5
- Target Price
- FINW $17.00
- VIGL $16.60
- AVG Volume (30 Days)
- FINW 12.3K
- VIGL 112.5K
- Earning Date
- FINW 10-24-2024
- VIGL 08-13-2024
- Dividend Yield
- FINW N/A
- VIGL N/A
- EPS Growth
- FINW N/A
- VIGL N/A
- EPS
- FINW 1.18
- VIGL N/A
- Revenue
- FINW $67,148,000.00
- VIGL N/A
- Revenue This Year
- FINW N/A
- VIGL N/A
- Revenue Next Year
- FINW $13.35
- VIGL N/A
- P/E Ratio
- FINW $12.15
- VIGL N/A
- Revenue Growth
- FINW 3.24
- VIGL N/A
- 52 Week Low
- FINW $8.31
- VIGL $2.47
- 52 Week High
- FINW $14.98
- VIGL $9.24
- Technical
- Relative Strength Index (RSI)
- FINW 74.87
- VIGL 52.08
- Support Level
- FINW $13.64
- VIGL $3.20
- Resistance Level
- FINW $13.25
- VIGL $4.03
- Average True Range (ATR)
- FINW 0.48
- VIGL 0.29
- MACD
- FINW 0.11
- VIGL 0.05
- Stochastic Oscillator
- FINW 92.54
- VIGL 57.83
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.